Investment Rating - The report gives a "Buy" rating for the company, indicating a positive outlook for its future performance [60]. Core Viewpoints - The company is a leading manufacturer in the personal hygiene care products sector in China, with a focus on disposable hygiene products such as baby diapers, adult diapers, menstrual pants, sanitary napkins, and wet wipes. It has accelerated its layout of proprietary brands and is expanding into the sanitary napkin market through the acquisition of Hubei Sibao Group [1][13]. - The diaper industry is expected to recover in 2025, driven by price increases, despite a projected decline in retail scale for 2024. The company is well-positioned to benefit from the recovery in newborn numbers and the expansion of production capacity [2][29]. - The sanitary napkin market is experiencing growth, with the company leveraging its newly acquired brand, Jieting, to drive sales through e-commerce channels and new product launches [3][47]. Summary by Sections Company Overview - The company has established itself as a leader in the manufacturing of personal hygiene products, with a strong focus on research and development. It has successfully partnered with high-quality clients and is expanding its proprietary brand portfolio [1][13]. Diaper Industry Outlook - The Chinese diaper market is projected to have a retail scale of approximately 41.1 billion yuan in 2024, with a decline in sales volume but stable average prices. The company is expected to benefit from a recovery in newborn numbers and the expansion of its production capacity [2][29]. Sanitary Napkin Market Dynamics - The sanitary napkin market is projected to grow, with a retail scale of about 99.5 billion yuan in 2024. The company is focusing on e-commerce and new product launches to enhance its market position [3][43]. Financial Forecast and Investment Recommendations - The company is expected to achieve a net profit of 4.6 billion yuan in 2025, with growth rates of 17.5%, 18.5%, and 20.0% for the following years. The current stock price reflects a lower PE ratio compared to peers, indicating potential for valuation improvement [4][60].

Core Viewpoint - The recovery of newborn population in 2024 has provided relief to maternal and infant-related listed companies, but long-term growth remains dependent on overcoming reliance on population dividends [1][2]. Group 1: Company Performance - In Q1 2024, Kidswant (孩子王) reported revenue of 2.4 billion yuan, a year-on-year increase of 9.5%, and net profit of 31.08 million yuan, up 166% [1]. - Aiyingshi (爱婴室) achieved Q1 2024 revenue of 860 million yuan, growing 6.6% year-on-year, with net profit of 6.694 million yuan, up 6.1% [1]. - The newborn population in China for 2024 was 9.54 million, an increase of 520,000 from the previous year, positively impacting the maternal and infant market [1]. Group 2: Revenue Drivers - The growth in revenue for Kidswant and Aiyingshi was primarily driven by core business milk powder sales, with revenues of 5.07 billion yuan and 2.1 billion yuan respectively, both showing year-on-year growth of 9.4% and 9.5% [2]. - In Q1 2025, Aiyingshi's milk powder revenue reached 530 million yuan, a 10.9% increase year-on-year, while sales of other products like toys also saw growth [2]. - Haoyue Care (豪悦护理) reported a 4.3% increase in infant hygiene product revenue to 2.06 billion yuan in 2024, contributing to an overall revenue of 2.93 billion yuan, reversing a decline from the previous year [2]. Group 3: Market Trends and Challenges - Analysts indicate that while the recovery in newborn numbers has contributed to performance, companies must diversify away from reliance on population growth due to the long-term decline in birth rates [3]. - Companies are exploring transformation paths, with Haoyue Care investing in adult incontinence products to capitalize on the aging population trend [3]. - The management of Yili has indicated potential slight declines in birth rates in 2025, reflecting ongoing challenges in the demographic landscape [3].